Geron Corp. (GERN) and GE Healthcare, a unit of General Electric Co. (GE), announced Tuesday morning that they entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening.
Geron Corp. gapped up sharply Tuesday, but was range-bound for the majority of the session. Shares closed higher by $0.98 at $7.67 on the highest volume in 5 months. The stock finished at a 4 1/2 month high.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.